Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination

Nautilus Biotechnology, Inc.

2021-Q2 EPS reported -$0.43

Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.
Q2 2021 operating expenses $10.7M (up 215% YoY); net loss $10.7M vs $3.4M in Q2 2020.
Cash and investments $388.4M as of June 30, 2021.
Appointed Emma Lundberg, Ph.D. to Scientific Advisory Board.
Planning platform commercialization in late-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.